Nolvadex 20 - Gen-Shi Laboratories

Developed during contraceptive research in the early 1960s, Tamoxifen citrate eventually became a leading anti-estrogen after showing efficacy in blocking estrogen receptors in breast tissue. Marketed as Nolvadex after FDA approval in 1977, it played a central role in the management of estrogen receptor-positive breast cancers. Beyond oncology, Tamoxifen was embraced by the fitness community for controlling estrogenic side effects and helping restore hormonal balance after anabolic steroid cycles.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Nolvadex 20 by Gen-Shi Laboratories, consult with your doctor or healthcare professional.